Safety Comparison of Pfizer-BioNTech, Moderna Vaccines Among US Veterans

JAMA Internal Medicine

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, JUNE 13, 2022

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2022.2109?guestAccessKey=1e60fb0a-d992-4a2c-b255-fd0bd4c0d1ef&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061322

 

About The Study: Researchers compared the risk of adverse events of the Pfizer-BioNTech and Moderna COVID-19 vaccines during 38 weeks of follow-up among 433,000 U.S. veterans.

Authors: Arin L. Madenci, M.D., Ph.D., of the Harvard T.H. Chan School of Public Health in Boston, is the corresponding author.

 

(doi:10.1001/jamainternmed.2022.2109)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.